Literature DB >> 3298936

Effect of porcine gastric inhibitory polypeptide on beta-cell function in type I and type II diabetes mellitus.

T Krarup, N Saurbrey, A J Moody, C Kühl, S Madsbad.   

Abstract

The effect of highly purified natural porcine GIP on C-peptide release was examined in six type I (insulin-dependent) diabetics (IDD) with residual beta-cell function, six type II non-insulin-dependent) diabetics (NIDD), and six normal subjects. All subjects were normal weight. From -120 minutes to 180 minutes glucose or insulin was infused IV to achieve a constant plasma glucose level of 8 mmol/L. On two separate days GIP (2 pmol/kg/min) or isotonic NaCl at random were infused from 0 to 30 minutes. After 10 minutes of GIP infusion plasma IR-GIP concentrations were in the physiologic postprandial range. At 30 minutes a further increase in IR-GIP to supraphysiologic levels occurred. In all subjects plasma, C-peptide increased more after 10 minutes of GIP infusion (IDD, 0.48 +/- 0.05; NIDD, 0.79 +/- 0.11; normal subjects, 2.27 +/- 0.29 nmol/L) than on the corresponding day with NaCl infusion (IDD, 0.35 +/- 0.03; NIDD, 0.62 +/- 0.08; normal subjects, 1.22 +/- 0.13 nmol/L, P less than .05 for all). The responses of the diabetics were significantly lower than that of the normal subjects (P less than .001 for both groups). No further increase in C-peptide occurred during the remaining 20 minutes of the GIP infusion in the diabetic subjects (IDD, 0.49 +/- 0.05; NIDD, 0.83 +/- 0.10 nmol/L). In the presence of a plasma glucose concentration of 8 mmol/L, physiologic concentrations of porcine GIP caused an immediate but impaired beta-cell response in IDD and NIDD patients.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3298936     DOI: 10.1016/0026-0495(87)90153-3

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  20 in total

Review 1.  Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins.

Authors:  Marzieh Salehi; Benedikt A Aulinger; David A D'Alessio
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

2.  Glycemic effect of pancreatic preproglucagon in mouse sleeve gastrectomy.

Authors:  Ki-Suk Kim; Chelsea R Hutch; Landon Wood; Irwin J Magrisso; Randy J Seeley; Darleen A Sandoval
Journal:  JCI Insight       Date:  2019-10-17

Review 3.  Incretins and the development of type 2 diabetes.

Authors:  Juris J Meier; Michael A Nauck
Journal:  Curr Diab Rep       Date:  2006-06       Impact factor: 4.810

Review 4.  Discovery, characterization, and clinical development of the glucagon-like peptides.

Authors:  Daniel J Drucker; Joel F Habener; Jens Juul Holst
Journal:  J Clin Invest       Date:  2017-12-01       Impact factor: 14.808

5.  Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.

Authors:  J J Meier; B Gallwitz; M Askenas; K Vollmer; C F Deacon; J J Holst; W E Schmidt; M A Nauck
Journal:  Diabetologia       Date:  2005-07-12       Impact factor: 10.122

6.  Comparative Intracerebroventricular and Intrathecal Administration of a Nanomolar Macrocyclic Melanocortin Receptor Agonist MDE6-5-2c (c[Pro-His-DPhe-Arg-Trp-Dap-Ala-DPro]) Decreases Food Intake in Mice.

Authors:  Danielle N Adank; Mary M Lunzer; Mark D Ericson; Zoe M Koeperich; Stacey L Wilber; Katlyn A Fleming; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2020-09-10       Impact factor: 4.418

7.  Role and development of GLP-1 receptor agonists in the management of diabetes.

Authors:  Chee W Chia; Josephine M Egan
Journal:  Diabetes Metab Syndr Obes       Date:  2009-05-15       Impact factor: 3.168

Review 8.  Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function?

Authors:  Juris J Meier; Michael A Nauck
Journal:  Diabetes       Date:  2010-05       Impact factor: 9.461

Review 9.  Incretins, insulin secretion and Type 2 diabetes mellitus.

Authors:  T Vilsbøll; J J Holst
Journal:  Diabetologia       Date:  2004-02-13       Impact factor: 10.122

10.  Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes.

Authors:  Chee W Chia; Olga D Carlson; Wook Kim; Yu-Kyong Shin; Cornelia P Charles; Hee Seung Kim; Denise L Melvin; Josephine M Egan
Journal:  Diabetes       Date:  2009-03-10       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.